← 返回

揭示 GINS1 的致癌和免疫调节作用:一项系统性泛癌研究

英文原题:Unraveling the oncogenic and immunomodulatory roles of GINS1: a systematic pan-cancer study.

查看英文原题

Unraveling the oncogenic and immunomodulatory roles of GINS1: a systematic pan-cancer study.

PubMed 2026/03/03(内容时间) Cancer Cell Int Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

GINS1 可作为可行的预后指标和治疗干预靶点,影响肿瘤进展和免疫调节。靶向 GINS1 可能为癌症管理提供新的治疗思路。

研究思路结论见上方概要

GINS1通过在GINS复合体中的核心作用介导DNA复制保真度和细胞周期调控。然而,其在多种癌症类型中的全面作用仍不清楚。本研究旨在系统分析GINS1在各类癌症中的关键功能。

我们利用泛癌和多组学数据集,并应用生存分析、免疫浸润评估、功能富集分析和基因组改变分析,以探索GINS1在多种癌症中的表达模式、预后意义、免疫浸润、基因组改变和潜在治疗相关性。最终,我们评估了GINS1在四种癌症类型中的诊断性能,并通过体外实验(包括集落形成、CCK-8、EdU和Transwell)验证了其在肾癌中的功能作用,证实GINS1敲低抑制细胞增殖并损害PI3K/AKT通路活性。

GINS1在31种癌症类型中显著上调,并与多种恶性肿瘤的不良预后相关。GINS1作为一种生物标志物,同时与肿瘤突变负荷(TMB)、微卫星不稳定性(MSI)以及跨肿瘤谱系的RNA m6A修饰相关。GINS1高表达与独特的免疫浸润模式显著相关,其特征为NKT细胞特征减少和Th2细胞富集增加。功能分析显示,GINS1参与细胞周期调控、DNA复制和致癌信号通路(PI3K-Akt、p53和NF-κB)。值得注意的是,生存分析表明GINS1表达影响免疫治疗反应,预测接受抗PD-1治疗的患者预后不良,但对抗PD-L1抑制剂的反应改善。GINS1在KIRP、LIHC、PAAD和SARC中表现出较强的诊断价值。在肾癌中,功能实验证实GINS1敲低显著抑制细胞增殖、迁移和侵袭,并减弱PI3K/AKT信号活性。

展开英文摘要原文

GINS1 mediates DNA replication fidelity and cell cycle regulation through its integral role in the GINS complex. However, its comprehensive role across diverse cancer types remains unclear. This study aimed to systematically analyze the critical functions of GINS1 across cancers.

We utilized pan-cancer and multi-omics datasets and applied survival analysis, immune infiltration assessment, functional enrichment analysis, and genomic alteration profiling to explore.

We utilized pan-cancer and multi-omics datasets and applied survival analysis, immune infiltration assessment, functional enrichment analysis, and genomic alteration profiling to explore expression patterns, prognostic significance, immune infiltration, genomic alterations, and potential therapeutic relevance of GINS1 across multiple cancers. Ultimately, we evaluated the diagnostic performance of GINS1 in four cancer types and validated its functional role in renal cancer through in vitro assays, including colony formation, CCK-8, EdU, and Transwell, confirming that GINS1 knockdown inhibits cell proliferation and impairs PI3K/AKT pathway activity.

GINS1 was significantly upregulated in 31 cancer types and correlated with poor prognosis in multiple malignancies. GINS1, as a biomarker, is concurrently linked to tumor mutational burden (TMB), microsatellite instability (MSI), and RNA m6A modification across tumor lineages. High GINS1 expression was significantly associated with distinct immune infiltration patterns, characterized by reduced NKT cell signatures and increased Th2 cell enrichment. Functional analysis revealed that GINS1 is involved in cell cycle regulation, DNA replication, and oncogenic signaling pathways (PI3K-Akt, p53, and NF-κB). Notably, survival analysis indicated that GINS1 expression affects the immunotherapy response, predicting poor outcomes in patients receiving anti-PD-1 therapy but an improved response to anti-PD-L1 inhibitors. GINS1 exhibited strong diagnostic value in KIRP, LIHC, PAAD, and SARC. In renal cancer, functional assays confirmed that GINS1 knockdown significantly suppressed cell proliferation, migration, and invasion, and attenuated PI3K/AKT signaling activity.

GINS1 serves as a viable prognostic indicator and target for therapeutic intervention, influencing both tumor progression and immune regulation. Targeting GINS1 may provide new therapeutic insights for cancer management.

论文信息

作者
Zhang X、Lei W、Pan Y、Zhong L、Zhai L、Li H、Liu B
第一作者单位
Department of Clinical Laboratory, Caner Hospital of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Kunming, 650118, Yunnan, China.China
通讯作者单位
Central Laboratory of Yong-Chuan Hospital, Chongqing Medical University, Chongqing, 402160, China. liubeizhong@cqmu.edu.cn.China
期刊
Cancer cell international2026 Mar 3
原文标识
PubMed 41776634 · DOI 10.1186/s12935-026-04252-z